Adenosquamous carcinoma of the head and neck: report of 20 cases and review of the literature.
Détails
ID Serval
serval:BIB_8C325269EDBB
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Adenosquamous carcinoma of the head and neck: report of 20 cases and review of the literature.
Périodique
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
ISSN
2212-4411 (Electronic)
Statut éditorial
Publié
Date de publication
2013
Peer-reviewed
Oui
Volume
116
Numéro
3
Pages
313-320
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish
Résumé
PURPOSE: To assess the clinical profile and prognostic factors in patients with adenosquamous carcinoma (ASC) of the head and neck treated by surgery and/or radiation therapy with or without chemotherapy.
METHODS: Data from 20 patients with stage I-II (n = 4), III (n = 5), or IVA (n = 11) head and neck ASC, treated between 1989 and 2010 were collected in a retrospective multicenter Rare Cancer Network study. Surgery was performed in 16 patients. Seventeen patients received combined modality treatment.
RESULTS: After a median follow-up of 15.5Â months, 12 patients recurred. The 3-year and median overall survival, disease-free survival (DFS), and loco-regional control were 52% and 39Â months, 32% and 12Â months, and 47% and 33Â months respectively. In multivariate analysis, DFS was negatively influenced by the presence of extracapsular extension and advanced stage.
CONCLUSION: Overall prognosis of locoregionally advanced ASC remains poor. However, early stage ASC patients managed with combined modality treatment may have prolonged DFS.
METHODS: Data from 20 patients with stage I-II (n = 4), III (n = 5), or IVA (n = 11) head and neck ASC, treated between 1989 and 2010 were collected in a retrospective multicenter Rare Cancer Network study. Surgery was performed in 16 patients. Seventeen patients received combined modality treatment.
RESULTS: After a median follow-up of 15.5Â months, 12 patients recurred. The 3-year and median overall survival, disease-free survival (DFS), and loco-regional control were 52% and 39Â months, 32% and 12Â months, and 47% and 33Â months respectively. In multivariate analysis, DFS was negatively influenced by the presence of extracapsular extension and advanced stage.
CONCLUSION: Overall prognosis of locoregionally advanced ASC remains poor. However, early stage ASC patients managed with combined modality treatment may have prolonged DFS.
Pubmed
Web of science
Création de la notice
12/09/2013 18:23
Dernière modification de la notice
20/08/2019 15:50
Données d'usage
